Annexon
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 71
- Market Cap
- $639.2M
- Website
- http://www.annexonbio.com
- Introduction
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Clinical Trials
24
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Drug: Tanruprubart
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Annexon, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT07020819
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Annexon, Inc.
- Target Recruit Count
- 630
- Registration Number
- NCT06510816
- Locations
- 🇺🇸
Retina Macula Institute of Arizona, Scottsdale, Arizona, United States
🇺🇸Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸RCOC Clinical Research Institute Inc, Fullerton, California, United States
A Study of ANX009 in Adult Participants With Lupus Nephritis
- Conditions
- Lupus Nephritis
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Annexon, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT05780515
- Locations
- 🇵🇭
Annexon Investigational Site 203, Angeles City, Philippines
🇵🇭Annexon Investigational Site 204, Iloilo City, Philippines
🇵🇭Annexon Investigational Site 201, Manila, Philippines
Dose Study of ANX1502 in Healthy Volunteers
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Annexon, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT05521269
- Locations
- 🇳🇱
Annexon Investigational Site 01, Groningen, Netherlands
Single Ascending Dose Study of ANX105
- Conditions
- Healthy
- Interventions
- Drug: PlaceboBiological: ANX105
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Annexon, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05288881
- Locations
- 🇳🇱
Annexon Investigational Site 02, Groningen, Netherlands
🇳🇱Annexon Investigational Site 01, Leiden, Netherlands
- Prev
- 1
- 2
- 3
- Next